Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RADPLAT and Tarceva in Locally Advanced Head and Neck Squamous Cell Carcinoma
NCT00304278Phase 2Completed
- Sponsor
- Southern Illinois University
- Start
- Mar 2006
- Primary completion
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of erlotinib in head and neck squamous cell carcinoma (HNSCC), sponsored by Southern Illinois University. Primary endpoint: Objective Response Rate (Complete and Partial Response) at 17 weeks. Started Mar 2006; status: completed.
02
Drugs
erlotinib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT00304278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00304278.